Pacira reports Q2 EPS 74c, consensus 71c

Reports Q2 revenue $181.1M, consensus $182.76M. “Throughout the second quarter, we continued to make important progress advancing our 5×30 growth strategy to accelerate topline growth and fuel our transition into an innovative biopharmaceutical organization,” said Frank Lee, chief executive officer of Pacira (PCRX) BioSciences. “We continue to focus on driving broad market adoption for EXPAREL. We are seeing encouraging momentum from leading indicators reinforcing our belief that EXPAREL is poised for sustainable growth and expanded market leadership.”